CN103356843A - Chitosan oligosaccharide compound preparation and application thereof to preparation of drugs for treating skin ulcers - Google Patents
Chitosan oligosaccharide compound preparation and application thereof to preparation of drugs for treating skin ulcers Download PDFInfo
- Publication number
- CN103356843A CN103356843A CN2012100862377A CN201210086237A CN103356843A CN 103356843 A CN103356843 A CN 103356843A CN 2012100862377 A CN2012100862377 A CN 2012100862377A CN 201210086237 A CN201210086237 A CN 201210086237A CN 103356843 A CN103356843 A CN 103356843A
- Authority
- CN
- China
- Prior art keywords
- preparation
- chitosan
- oligo
- application
- chitosan oligosaccharide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a chitosan oligosaccharide preparation. The preparation is a solution prepared from a chitosan oligosaccharide solution, salvia extracts, sangusis draconis extracts and borneol. Every 100ml of chitosan oligosaccharide solution contains 1-1.5g of salvia extracts, 1.5-2g of sangusis draconis extracts and 1ml of polyhexamethylene guanidine. The invention also provides an application of the chitosan oligosaccharide preparation to drug preparation, including an application to preparation of drugs for treating skin ulcers such as chronic ulcer of leg, failure of healing of wounds and surgical incisions and the like. The preparation has bactericidal effects on staphylococcus aureus, escherichia coli and pseudomonas aeruginosa. The preparation is favorable for solving the problem of the film forming property of chitosan oligosaccharide and can fully act on the wounded parts, thus improving the curative effects; and on the other hand, the preparation has good bactericidal effects, can not only promote wound healing but also avoid re-infection, achieves healing effects on clinical skin ulcers, is favorable for solving the clinical medical problems and has great clinical application values.
Description
Technical field
The present invention relates to pharmaceutical preparation, be specifically related to a kind of oligo-chitosan preparation and in the medicine of preparation treatment skin ulcer, use.
Background technology
Oligo-chitosan (oligochitosan) is the high-end derivant of chitin, is to contain amino oligosaccharide, is referred to as the edibility animal fiber, and it is unique small-molecule substance with positive charge in the natural polysaccharide, and has stable space structure.At present the functional study that is directed to oligo-chitosan has been carried out in the whole world, and result of study shows, oligo-chitosan is the multi-functional saccharide of a class.Oligo-chitosan can form the polysaccharide body of glucamine and acetylglucosamine after by metabolism, and these all are the necessary materials of human body cell, and oligo-chitosan can be removed the free radical in the body with positive charge.Concrete function has: 1. balance the body function: remove free radical, prevent from wearing out, improving cardiovascular and cerebrovascular vessel, regulate blood fat, strengthen immunoloregulation function, increase the gastrointestinal profitable strain.2. promote the reparation of cell.3. treat and prophylaxis of cancer.4. antibacterial: to the gastrointestinal escherichia coli, staphylococcus aureus, green coccus, gram rigidity bacterium etc. has obvious inhibitory action.The inventor has done further research to oligo-chitosan, studies its new pharmaceutical preparation, and finds that it has the purposes for the treatment of dermatosis.Summary of the invention
Technical problem to be solved by this invention is research design oligo-chitosan compound preparation and the application in pharmacy thereof.
The invention provides a kind of oligo-chitosan preparation, the solution that it is comprised of oligopolymerization chitosan sugar juice, Radix Salviae Miltiorrhizae extract, Sanguis Draxonis extract; Wherein contain 1-1.5g Radix Salviae Miltiorrhizae extract, 1.5-2g Sanguis Draxonis extract and 1ml polyhexamethylene list guanidine in every 100ml oligopolymerization chitosan sugar juice.Preferably, contain 1g Radix Salviae Miltiorrhizae extract, 2g Sanguis Draxonis extract and 1ml polyhexamethylene list guanidine in every 100ml oligopolymerization chitosan sugar juice.
Oligopolymerization chitosan sugar juice of the present invention is mixed to get by oligo-chitosan 15g and glycerol 10ml, ethanol 20ml and water 55ml.
Described oligo-chitosan is that molecular weight is the oligo-chitosan of 500-30000.
Described oligo-chitosan prepares (conventional hydrogen peroxide preparation method) by following method:
In the glass reaction still of 50L, add 20kg pure water (deionized water), the chitosan that adds 2kg, stir first 10min, then the hydrogen peroxide that adds 15kg, slowly add, temperature is controlled in 45 ℃, hydrogen peroxide to be added, continue to keep 45 ℃ and stir 2h, then be cooled to room temperature (25 ℃), the filtering solid impurity is adjusted pH value to neutral, be distilled to 1/3 of original volume, pour in 95% ethanol of equal volume, get the oligo-chitosan solid, leach, 50 ℃ of oven dry, weighing 1.55kg.
The raw materials such as described glycerol, ethanol, Radix Salviae Miltiorrhizae extract, Sanguis Draxonis extract and polyhexamethylene list guanidine can commercially availablely obtain.
Another object of the present invention has provided the application of described oligo-chitosan preparation in preparation treatment skin ulcer medicine.
The invention provides the application of described oligo-chitosan preparation in preparation treatment chronic ulcer of lower extremity medicine.
The invention provides described oligo-chitosan preparation in the more application in the medicine of preparation treatment wound and operative incision.
The inventor carries out described oligo-chitosan preparation to Elastolyticenzyme of pseudomonas aeruginosa, staphylococcus aureus, colibacillary bactericidal assay, and the result shows has bactericidal action to staphylococcus aureus, escherichia coli, and Pseudomonas aeruginosa is had bactericidal action.
Oligo-chitosan preparation of the present invention reaches the result of healing to the treatment of clinical skin ulcer, wound and operative incision, has solved these difficult problems that run on the clinical medicine.
The invention solves the film property of oligo-chitosan, medicine can fully act on the affected part, improves curative effect; On the other hand, have good bactericidal effect, not only promote wound healing, can also avoid reinfect, very large clinical value is arranged.
Description of drawings
Fig. 1, Fig. 2 treat healing state.
The specific embodiment
Embodiment 1 oligo-chitosan prepares (conventional hydrogen peroxide preparation method) by following method:
In the glass reaction still of 50L, add 20kg pure water (deionized water), chitosan (the Suzhou Ruimei Biotechnology Co., Ltd. that adds 2kg, 98% content) stir first 10min, then add the hydrogen peroxide (the prosperous and powerful chemical reagent company limited in Suzhou, 30% concentration) of 15kg, slowly add, temperature is controlled in 45 ℃, hydrogen peroxide to be added continues to keep 45 ℃ and stirs 2h, then is cooled to room temperature (25 ℃), the filtering solid impurity, NaOH regulates pH value to neutral, is distilled to 1/3 of original volume, pours in 95% alcoholic solution of equal volume, get the oligo-chitosan solid, leach 50 ℃ of oven dry, weighing 1.55kg.
Detect through the HPLC standard control, confirm as molecular weight 500-30000 oligo-chitosan.
The preparation of embodiment 2 oligopolymerization chitosan sugar juices
Oligo-chitosan (embodiment 1 preparation) 15g and glycerol (the prosperous and powerful chemical reagent company limited in Suzhou, 99% concentration) 10ml, ethanol (the prosperous and powerful chemical reagent company limited in Suzhou, 95% concentration) 20ml and water 55ml are mixed to get.
The preparation of embodiment 3 oligo-chitosan preparations
Extract) and 1ml polyhexamethylene list guanidine (Shanghai Hipoly Industry Co., Ltd., 25%) with 1g Radix Salviae Miltiorrhizae extract (Shaanxi Rui Kang biological engineering company limited, 10: 1 medical materials: extract) with 2g Sanguis Draxonis extract (Shaanxi Rui Kang biological engineering company limited, 8: 1 medical materials:
Join in the oligopolymerization chitosan sugar juice that 100ml embodiment 2 makes, mix homogeneously, ultraviolet sterilization, and get final product.
The preparation of embodiment 4 oligo-chitosan preparations
1g Radix Salviae Miltiorrhizae extract and 2g Sanguis Draxonis extract and 1ml polyhexamethylene list guanidine.
Method is with embodiment 3.
The preparation of embodiment 5 oligo-chitosan preparations
1.5g Radix Salviae Miltiorrhizae extract and 1.5g Radix Astragali extract and 1ml polyhexamethylene list guanidine.
Method is with embodiment 3.
The filming performance research experiment of embodiment 6 oligo-chitosan
With the oligo-chitosan that embodiment 1 makes, with glycerol, ethanol, water, polyhexamethylene list guanidine hybrid modulation, observe its film property according to a certain percentage, experimental result is as follows:
Annotate: the water solublity of oligo-chitosan is dissolving 40g solid in every 100g water.
Carried out simultaneously oligo-chitosan content between the 1-10g scope and the film property between 20g-30g test, the former viscosity is low to be difficult to form preferably film, and latter is that the excessive oligo-chitosan of viscosity is difficult to whole dissolvings, to sum up state, we have chosen group No. 1, and its film forming speed is fast, and viscosity is moderate.
The bacteriostatic test of embodiment 5. preparations of the present invention: to Elastolyticenzyme of pseudomonas aeruginosa, staphylococcus aureus, colibacillary bactericidal assay
Equipment: test organisms:
Pseudomonas aeruginosa (ATCC15442) the 5th generation (Military Medical Science Institute Disinfection examination center provides)
Staphylococcus aureus (ATCC6538) the 5th generation (Military Medical Science Institute Disinfection examination center provides)
Colibacillary sterilization (8099) the 5th generation (Military Medical Science Institute Disinfection examination center provides)
The phosphate buffer of PBS:0.03%
Culture medium: ordinary nutrient agar
The oligo-chitosan preparation that test specimen: embodiment 3 makes
Test temperature: 20 ℃ ± 1 ℃
Test method: under 20 ℃ ± 1 ℃, with test specimen effect Pseudomonas aeruginosa, staphylococcus aureus, escherichia coli, action time 2min, 5min, 10min, 20min, viewing test result:
Test repeats 3 times
Experimental result: test temperature is at 20 ℃ ± 1 ℃, and sample effect had bactericidal action to staphylococcus aureus, escherichia coli in the time of 2 minutes, when acting on 5 minutes Pseudomonas aeruginosa is had bactericidal action.
Embodiment 6 clinical treatments
The oligo-chitosan preparation that preparation: embodiment 3 makes
Case: 18 examples, 10 routine male wherein, 8 routine women; Chronic ulcer of lower extremity 11 examples, otch wound surface 7 examples more after the operation; Wound surface area 4cm
2-20cm
2, average 12cm
2
Therapeutic Method:
1. chronic ulcer of lower extremity treatment: wound surface with iodophor disinfection after conventional debridement treatment, clean wound surface with normal saline, antiseptic gauze is dried, then the oligo-chitosan preparation is applied in the surface, apply one deck after to be filmed, each use amount 0.5-1.5ml fixes with sterile gauze again, and every 6h changes dressings once.
2. operative incision is not healed: wound surface with iodophor disinfection after conventional debridement treatment, clean wound surface with normal saline, antiseptic gauze is dried, then the oligo-chitosan preparation is applied in the surface, applies again one deck after to be filmed, fix with sterile gauze, each use amount 1-3.5ml, every 4h changes dressings once.
Observation of curative effect:
1 anaphylaxis: observe the part and have or not pruritus, erythema, the skin allergy symptoms such as chickenpox or erosion.
2 infection controls: the variation according to skin ulcer face purulence thing before and after using is judged, is reduced to effectively, unchanged or increase to invalid.
3 wound healing times: the record from from the drug application to the required time of wound healing.
The result:
Have no adverse reaction, infect without increasing, the chronic ulcer of lower extremity treatment: the average healing is 20 days; Operative incision is not healed: the average healing is 7 days, and preferably therapeutic effect is arranged.
Claims (7)
1. an oligo-chitosan preparation is characterized in that, the solution that it is comprised of oligopolymerization chitosan sugar juice, Radix Salviae Miltiorrhizae extract, Sanguis Draxonis extract and polyhexamethylene list guanidine; Wherein contain 1-1.5g Radix Salviae Miltiorrhizae extract, 1.5-2g Sanguis Draxonis extract and 1ml polyhexamethylene list guanidine in every 100ml oligopolymerization chitosan sugar juice.
2. an oligo-chitosan preparation is characterized in that, the solution that it is comprised of oligopolymerization chitosan sugar juice, Radix Salviae Miltiorrhizae extract, Sanguis Draxonis extract and polyhexamethylene list guanidine; Wherein contain 1g Radix Salviae Miltiorrhizae extract, 2g Sanguis Draxonis extract and 1ml polyhexamethylene list guanidine in every 100ml oligopolymerization chitosan sugar juice.
3. preparation according to claim 1 and 2 is characterized in that, described oligopolymerization chitosan sugar juice is mixed to get by oligo-chitosan 15g and glycerol 10ml, ethanol 20ml and water 55ml.
4. preparation according to claim 1 and 2 is characterized in that, described oligo-chitosan is that molecular weight is the oligo-chitosan of 500-30000; Described oligo-chitosan prepares by following method:
In the glass reaction still of 50L, add the 20kg pure water, add the chitosan of 2kg, stir first 10min, then the hydrogen peroxide that adds 15kg slowly adds temperature and is controlled in 45 ℃ hydrogen peroxide to be added, continue to keep 45 ℃ and stir 2h, then be cooled to room temperature, the filtering solid impurity, NaOH regulates pH value to neutral, be distilled to 1/3 of original volume, pour in the alcoholic solution of equal volume, get the oligo-chitosan solid, leach 50 ℃ of oven dry, weighing 1.55kg.
5. the oligo-chitosan preparation is used in the medicine of preparation treatment skin ulcer as claimed in claim 1.
6. application according to claim 5 is characterized in that, the application of described oligo-chitosan preparation in preparation treatment chronic ulcer of lower extremity medicine.
7. application according to claim 5 is characterized in that, described oligo-chitosan preparation is in the more application in the medicine of preparation treatment wound and operative incision.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012100862377A CN103356843A (en) | 2012-03-28 | 2012-03-28 | Chitosan oligosaccharide compound preparation and application thereof to preparation of drugs for treating skin ulcers |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012100862377A CN103356843A (en) | 2012-03-28 | 2012-03-28 | Chitosan oligosaccharide compound preparation and application thereof to preparation of drugs for treating skin ulcers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103356843A true CN103356843A (en) | 2013-10-23 |
Family
ID=49359645
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012100862377A Pending CN103356843A (en) | 2012-03-28 | 2012-03-28 | Chitosan oligosaccharide compound preparation and application thereof to preparation of drugs for treating skin ulcers |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103356843A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107789480A (en) * | 2016-08-30 | 2018-03-13 | 苏州瑞美科生物技术有限公司 | A kind of pharmaceutical composition for being used to treat canker sore |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1382480A (en) * | 2002-05-15 | 2002-12-04 | 李高霖 | Non-scar plaster for treating trauma and its preparing process and usage |
| CN1393230A (en) * | 2001-06-26 | 2003-01-29 | 李为 | Prescription for composite medicinal film prepared from chitosan and Chinese-medicinal materials |
| CN1602891A (en) * | 2004-07-27 | 2005-04-06 | 张英伟 | Glucosidase oral liquid |
| CN1969801A (en) * | 2005-11-25 | 2007-05-30 | 王立君 | Application of water soluble chitosan in toothpaste and mouthwash |
-
2012
- 2012-03-28 CN CN2012100862377A patent/CN103356843A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1393230A (en) * | 2001-06-26 | 2003-01-29 | 李为 | Prescription for composite medicinal film prepared from chitosan and Chinese-medicinal materials |
| CN1382480A (en) * | 2002-05-15 | 2002-12-04 | 李高霖 | Non-scar plaster for treating trauma and its preparing process and usage |
| CN1602891A (en) * | 2004-07-27 | 2005-04-06 | 张英伟 | Glucosidase oral liquid |
| CN1969801A (en) * | 2005-11-25 | 2007-05-30 | 王立君 | Application of water soluble chitosan in toothpaste and mouthwash |
Non-Patent Citations (1)
| Title |
|---|
| 朱孔营；等: "低分子量壳聚糖制备与应用研究进展", 《高分子通报》, no. 2, 31 December 2006 (2006-12-31), pages 41 - 45 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107789480A (en) * | 2016-08-30 | 2018-03-13 | 苏州瑞美科生物技术有限公司 | A kind of pharmaceutical composition for being used to treat canker sore |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Saikaly et al. | Honey and wound healing: an update | |
| Oryan et al. | Biological properties and therapeutic activities of honey in wound healing: A narrative review and meta-analysis | |
| Negut et al. | Treatment strategies for infected wounds | |
| CN109646712B (en) | Colloidal sulfur liquid dressing and preparation method thereof | |
| CN105012993A (en) | Medical and antibacterial cationic biogel dressing and preparation method thereof | |
| CN107998107A (en) | A kind of degerming gel of anti-inflammatory containing honey | |
| US20220143101A1 (en) | Collagen Membrane or Matrix with Antimicrobial Properties | |
| Yahia et al. | Quantitative evaluation of diabetic foot wound healing using hydrogel nanosilver based dressing vs. traditional dressing: A prospective randomized control study | |
| CN103356844B (en) | A kind of oligo-chitosan compound preparation and preparation treatment dermatosis medicine in apply | |
| Kucharzewski et al. | Stan scheller: the forerunner of clinical studies on using propolis for poor and chronic nonhealing wounds | |
| Jia et al. | Dynamic microenvironment-adaptable hydrogel with photothermal performance and ROS scavenging for management of diabetic ulcer | |
| Jafari et al. | Lucillia Sericata larval therapy in the treatment of diabetic chronic wounds | |
| CN103356843A (en) | Chitosan oligosaccharide compound preparation and application thereof to preparation of drugs for treating skin ulcers | |
| CN104474536A (en) | Fresh agrimonia pilosa medicine preparation for treating wounds | |
| Cigna et al. | Diabetic foot infection treatment and care | |
| Adinortey et al. | Honey as a natural product worthy of Re-consideration in treating MRSA wound infections | |
| Haycocks et al. | Use of a DACC-coated antimicrobial dressing in people with diabetes and a history of foot ulceration | |
| CN106237029B (en) | A kind of aloe antibiotic gel and preparation method thereof | |
| CN108042654A (en) | A kind of preparation process of the anti-inflammatory degerming gel containing honey | |
| Raducu et al. | Use of polyhexanidine in treating chronic wounds | |
| CN104147044B (en) | Composition for treating piglet staphylococcal exudative epidermitis | |
| Zbuchea | Honey, food and medicine: scientific rationale and practical efficiency in external administration of medicinal honey for wound healing | |
| Zubakha et al. | Combination of ultraviolet radiation of autologous blood, negative pressure wound therapy, and endolymphatic antibacterial therapy in the treatment of post-traumatic wound infections | |
| Keerthi et al. | A preliminary study on the effects of an antibacterial steroidal saponin from Borassus flabellifer L. fruit, on wound healing | |
| Watts et al. | Evidence summary: Wound management-low resource communities: Citric acid as a topical antiseptic |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20131023 |